In conclusion, our current study provides compelling evidence for the potential benefits of introducing GLP-1 receptor agonists and SGLT-2 inhibitors for managing type 2 diabetes mellitus in LMICs. The gene discussed is GLP1R; the disease is diabetes mellitus.